Subscribe
shutterstock_1106804450_penpics_studio
PENpics Studio / Shutterstock.com
5 August 2021GenericsSophie Topham

UK experimental use exemptions: Part 3—the expanded exemption

In the third article of a four-part series on experimental use exemptions from infringement in the UK, we consider the expansion of the original experimental use exemption (Section 60(5)(b) UK Patents Act [UKPA] 1977) introduced by the Legislative Reform (Patents) Order 2014/1997.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

More features

Startup challenges rival over brain monitoring tech at ITC
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
Regeneron hits Amgen over its blockbuster eye disease treatment
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
Novo Nordisk patent lapse opens door for Canadian Ozempic generics
Three reasons why the UK should reconsider joining the UPC
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies